Journal of Clinical Oncology
Articles in this Issue
Azenosertib plus paclitaxel for platinum-resistant ovarian cancer: Results from a phase 1b study.
5529 Background: Most patients (pts) with ovarian cancer develop platinum-resistant disease following surgery and platinum...
Integrated spatial transcriptomics, single-nucleus RNA sequencing, and histopathology to reveal immune-suppressive niches in colorectal cancer liver metastases.
e15544 Background: Progression of colorectal cancer (CRC) is shaped by interactions between tumor, immune, and stromal cel...
Does BMA improve outcomes in mHSPC with bone metastases?: Landmark propensity-matched analysis and nested zoledronic acid vs denosumab.
e17100 Background: Bone Marrow Agent (BMA) reduces skeletal-related events in bone-metastatic mCRPC, but their role in met...
The diagnostic delay signature in rare gynecologic cancers: Assessment of emergency presentation, acute organ failure, and failure-to-rescue.
e23143 Background: Rare gynecologic cancers lack standardized diagnostic pathways and are underrepresented in trials. Rari...
Determinants of triple-negative breast cancer among African patients: Early results from The African Cancer Atlas.
1133 Background: Triple-negative breast cancer (TNBC) is disproportionately common among women of African ancestry and is...
Genomic predictors of response to cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC): A real-world analysis from the PROMISE registry.
5066 Background: Cabazitaxel (Cabazi) is an important treatment for refractory mCRPC, but responses are heterogeneous. Hom...
Viral vs non-viral combined hepatocellular–cholangiocarcinoma: Distinct genomic landscapes and survival outcomes.
e16292 Background: Combined hepatocellular–cholangiocarcinoma (cHCC-CCA) is a rare and biologically heterogeneous primary...
HIPEC combined with PD-1 inhibitor, chemotherapy in conversion therapy for advanced gastric cancer with peritoneal metastasis: Results from a single-arm phase II clinical study.
e16077 Background: Patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC) accompanied by peritoneal...
Assessing adoption of neoadjuvant therapy in early-stage resectable non–small cell lung cancer: A retrospective review.
e20081 Background: Neoadjuvant therapy (NAT) has become standard of care for selected patients with resectable non–small c...
SOLAR: A post-approval study evaluating longitudinal performance of a blood-based test for screening individuals at average risk for colorectal cancer (CRC).
TPS10632 Background: CRC is a leading cause of cancer-related mortality; CRC screening has been shown to reduce mortality...
The association between cardiovascular disease risk and breast arterial calcifications identified on screening mammography: A retrospective study.
12026 Background: Screening mammography enables early breast cancer detection and improves outcomes. Breast cancer and car...
RALLY-MF: Initial efficacy of a phase 2 study of DISC-0974, an anti-hemojuvelin antibody, to treat anemia in myelofibrosis.
6501 Background: Hepcidin, a central regulator of iron homeostasis, is pathologically elevated in patients with myelofibro...
Circulating tumor DNA <i>NRAS</i> and <i>TP53</i> mutations to identify ultra-high-risk primary refractory myeloma patients.
7557 Background: Approximately 5% of newly diagnosed multiple myeloma (MM) patients progress on bortezomib-containing firs...
Determinants of accrual speed in U.S. phase III therapeutic cancer clinical trials.
e23001 Background: Patient accrual remains the dominant rate-limiting step in cancer clinical trials, driving unde...
G8 screening-defined geriatric vulnerability as a predictor of survival and quality of life in older patients with advanced cancer treated with novel therapies.
1663 Background: Older patients with advanced cancer are a highly heterogeneous population, in whom geriatric vulnerabilit...
Integrating AI-derived lung cancer risk and social determinants of health to improve risk stratification in a safety net lung cancer screening program.
11081 Background: Lung cancer screening (LCS) outcomes remain inequitable, with social and environmental determinants of h...
Atrial fibrillation mortality among patients with neoplasms: National trends and deep learning forecast through 2038.
e24027 Background: Atrial fibrillation (AFib) is the most common cardiac arrhythmia globally and has emerged as a prevalen...
Utilization of CEACAM7 as a novel diagnostic biomarker of pancreatic cancer.
e16421 Background: The trends of pancreatic cancer (PanCa) incidence and mortality are on a rising pattern. Pancreatic duc...
Fair inclusion in clinical trials: Updated Good Pharma Scorecard evaluations of FDA oncology drugs approved by the FDA, 2018-2023.
11030 Background: Adequate representation of demographic subgroups in clinical trials is essential for understanding the s...
Genetic characteristics of combined hepatocellular-cholangiocarcinoma tumors in a tertiary care center: A case series.
e16215 Background: Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare malignancy (1) with a 5-year OS as low a...
Early integrated rehabilitation and risk of distant metastases in breast cancer patients: A prospective controlled study.
e12701 Background: Integrated rehabilitation improves quality of life in breast cancer patients, but its impact on long-te...
A phase 1/2 study of the next-generation nectin-4–targeting antibody-drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic cervical cancer.
5508 Background: CRB-701 is a next-generation Nectin-4–targeted monomethyl auristatin E (MMAE)-based antibody–drug conjuga...
Safety and objective response of KRAS G12C inhibitors versus docetaxel in previously treated advanced NSCLC: Meta-analysis of randomized trials.
e20747 Background: Patients with previously treated KRAS G12C–mutated advanced non–small cell lung cancer (NSCLC) have lim...
Association of Palmar-plantar erythrodysesthesia syndrome (PPES), hypothyroidism, and clinical outcomes in previously treated endometrial cancer (EMC) with pMMR status: A subgroup analysis of FRUSICA-1.
e17612 Background: FRUSICA-1(NCT03903705) is an open label, single-arm, pivotal phase II study, demonstrated the promising...
Pathologic response and surgical conversion after preoperative docetaxel, cisplatin, and oral 5-FU with or without PD-1 inhibitors in resectable HNSCC: A retrospective cohort study.
e18072 Background: Induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) has been widely used in patien...